Clinical Trials
Clinical and outcomes research under the direction of the Department of Dermatology is conducted both at the Northwestern University Feinberg School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago dermatology clinics. For more information about the research or participation, please call our office at 312-503-5944.
Feinberg Clinical Trials
Scientists at the medical school are conducting hundreds of clinical trials daily. Learn more about our work via the Feinberg Office of Research Clinical Trials page.
Trials |
---|
DERMATOLOGY TISSUE ACQUISITION AND REPOSITORYThis study is collecting skin, hair, nail, blood,saliva, skin and/or buccal swabs, and mucous membrane (part of your skin which lines bodypassages and cavities such as the inside of your mouth or nose), and other tissue samples for usein a biorepository. By operating this biorepository, the Department of … This study is collecting skin, hair, nail, blood,saliva, skin and/or buccal swabs, and mucous membrane (part of your skin which lines bodypassages and cavities such as the inside of your mouth or nose), and other tissue samples for usein a biorepository. By operating this biorepository, the Department of Dermatology hopes todevelop a better understanding of skin diseases (meaning the knowledge about how cells in theskin behave and react to medical treatments) among researchers at Northwestern University andother approved researchers. This basic knowledge is expected to help the development of moreeffective patient care and new treatment methods.
STU00009443 |
Epidermolysis Bullosa Clinical Characterization and Outcomes DatabaseThe aim this study is to collaboratively advance knowledge about epidermolysis bullosa (EB) by collecting clinical data from patients with EB from multiple EB centers in the United States and Canada. As EB is a rare disease, coordination and collaboration between multiple centers will help our understanding of disease manifestations, … The aim this study is to collaboratively advance knowledge about epidermolysis bullosa (EB) by collecting clinical data from patients with EB from multiple EB centers in the United States and Canada. As EB is a rare disease, coordination and collaboration between multiple centers will help our understanding of disease manifestations, course, and complications, with the aim of improving future care, expanding clinical and translational research, and finding an eventual cure for individuals with EB. |
Characterization of the microbiome in cutaneous T cell lymphomaThe purpose of this study is to investigate the organisms that reside on the skin, in the gut, and nasal cavity and study their relationship with Cutaneous T-Cell Lymphoma (CTCL).
STU00209226 |
A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Subjects ((≥6 To <18 Years of Age)The purpose of this research study is to see if guselkumab is safe and effective for treating patients with chronic plaque psoriasis, and to find out how long guselkumab stays in and acts on the body and how the body reacts to it. This is shown by laboratory blood tests. … The purpose of this research study is to see if guselkumab is safe and effective for treating patients with chronic plaque psoriasis, and to find out how long guselkumab stays in and acts on the body and how the body reacts to it. This is shown by laboratory blood tests. Another purpose is to find out if guselkumab can cause side effects (unexpected or unwanted reactions from taking a drug). You could be in this study if:
NCT03451851 STU00209613 |
A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin ConditionsThe purpose of this research is to observe patients with skin conditions in a ‘real world’ setting and to create an patient registry of skin conditions, to better understand these diseases and how they are treated. A patient registry is a collection of information about a group of patients who … The purpose of this research is to observe patients with skin conditions in a ‘real world’ setting and to create an patient registry of skin conditions, to better understand these diseases and how they are treated. A patient registry is a collection of information about a group of patients who share a condition or experience. Additionally, researchers are interested in:
|
A PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF OQL011 ON VEGFR INHIBITOR-ASSOCIATED HAND-FOOT SKIN REACTION IN CANCER PATIENTSThis study is trying to determine whether an ointment is safe and effective for the treatment of hand-foot skin reaction induced by VEGRF inhibitors. Participants must be over the age of 18 and have hand-foot skin reaction after taking anti-cancer medications calls VEGRF inhibitors.
NCT04088318 STU00211322 |
Impact of immunotherapy-related skin diseases on quality of lifeThe purpose of this study is to characterize the effects of cutaneous side effects from immunotherapies on quality of life. Participants will complete a one time survey. |
Tape Strip Analysis in Dermatologic DiseasesThe main purpose of this study is to better understand the characteristics of various dermatologic diseases compared to healthy controls. The research team will do this by acquiring tape strips from subjects, a quick, painless, and non-invasive way to obtain skin cells. This study will collect tape strip samples … The main purpose of this study is to better understand the characteristics of various dermatologic diseases compared to healthy controls. The research team will do this by acquiring tape strips from subjects, a quick, painless, and non-invasive way to obtain skin cells. This study will collect tape strip samples from a broad range of dermatologic diseases, which may include psoriasis, epidermolysis bullosa, atopic dermatitis, ichthyosis, and other rare conditions, in addition to healthy controls. |
A Prospective and Retrospective Clinical, Histological and Molecular Analysis of the Spectrum of Cutaneous Presentations in Adult Patients Admitted to the HospitalThe purpose of this study is to better characterize and understand the spectrum of skin disease evaluated in the inpatient hospital setting.… The purpose of this study is to better characterize and understand the spectrum of skin disease evaluated in the inpatient hospital setting. |
A phase 1, open-label, safety and dosing study of autologous desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in subjects with active, anti-DSG3, mucosal-dominant pemphigus vulgarisThe purpose of this study is to determine the highest dose of the study drug that can be given safely to patients with pemphigus vulgaris. The study will test how the study drug affects desmoglein 3 (DSG3) autoantibody amounts in your body. DSG3 is responsible for holding together the cells … The purpose of this study is to determine the highest dose of the study drug that can be given safely to patients with pemphigus vulgaris. The study will test how the study drug affects desmoglein 3 (DSG3) autoantibody amounts in your body. DSG3 is responsible for holding together the cells lining the inside of the mouth, nose, throat, eyelids and genitals, causing the painful blisters commonly seen in patients with pemphigus vulgaris. The study will also look at how long the study drug stays in your body, and if the study drug improves the symptoms that you are experiencing with the pemphigus vulgaris.
NCT04422912 STU00214626 |
A Phase 3 Study of Tapinarof for the Treatment of Plaque Psoriasis in Pediatric SubjectsThis study is being done to evaluate the safety and tolerability of tapinarof cream, 1% in children and adolescents with plaque psoriasis. This study will also measure the quantity of the study drug in your blood, if any. The efficacy, how well the study drug works, will also be evaluated.… This study is being done to evaluate the safety and tolerability of tapinarof cream, 1% in children and adolescents with plaque psoriasis. This study will also measure the quantity of the study drug in your blood, if any. The efficacy, how well the study drug works, will also be evaluated. |
Investigation of Sleep and Health Outcomes in Women Reporting Normal and Heavy Menses FlowWe are interested in understanding how the menstrual cycle and severity of menses (lheavier menstrual flow) affects sleep.
STU00215465 |
Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaThe purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, … The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, ruxolitinib may cause T or NK-cell lymphomas to shrink.
NCT02974647 STU00216438 |
Development and Validation of an Ancillary Diagnostic Test for Mycosis Fungoides (SIGNAL MF)As the number of available treatments for CTCL grow, there is a need to find a way to identify which treatment will work best for each subject. The goal of this study is to develop a test called a gene expression assay to see if the assay can predict treatment … As the number of available treatments for CTCL grow, there is a need to find a way to identify which treatment will work best for each subject. The goal of this study is to develop a test called a gene expression assay to see if the assay can predict treatment success and/or failure in subjects with CTCL. Patient who has a diagnosis of mycosis fungoides (MF). Patient who is between 2-89 years of age. Patient who is willing and able to provide new skin samples via superficial scraping at least one affected and non-affected body site. STU00217977 |
Combing topical imiquimod with local radiotherapy treatment of mycosis fungoidesThe primary aim of this study is to assess the safety and efficacy of a combination local radiotherapy and topical imiquimod approach for the treatment of conventional (CD4+) mycosis fungoides (MF). Subjects will be asked to use the imiquimod cream at designated lesions nightly for 5 consecutive days a week … The primary aim of this study is to assess the safety and efficacy of a combination local radiotherapy and topical imiquimod approach for the treatment of conventional (CD4+) mycosis fungoides (MF). Subjects will be asked to use the imiquimod cream at designated lesions nightly for 5 consecutive days a week over 6 weeks. One week into the imiquimod treatment course, radiation therapy will be administered at Northwestern Medicine by radiation oncologists familiar with radiation treatment in 2 fractions of 4 Gy (units of radiation absorbed by the patient) (total 8 Gy) over 2 days to the same designated lesions. In addition, subjects will have two skin biopsies during the screening period and again at the same locations at week 8. Patients must have confirmed stage IA-IIB mycosis fungoides, have failed at least one standard therapy for MF, have active, but stable disease for at least 6 months with 4 or more discrete lesions (with at least 2 lesions >50cm2 in area combined). Patients of child bearing potential must have a negative pregnancy test before enrolling on the study.
NCT05838599 STU00218514 |
Hair Disorder RegistryThe purpose of this study is to collect characteristic data from patients with medical conditions affecting hair health using medical records and surveys. The main benefit of being in this study is to provide future benefit to patients with acquired and congenital hair disorders and the providers who care for … The purpose of this study is to collect characteristic data from patients with medical conditions affecting hair health using medical records and surveys.
The main benefit of being in this study is to provide future benefit to patients with acquired and congenital hair disorders and the providers who care for them by adding to our understanding of normal hair physiology, causes and mechanisms of disease, clinical and molecular features, natural history, and treatment outcomes. |
An Open-Label Study of Dupilumab in Adolescent and Adult Skin-of-Color Patients with Moderate-to-Severe Atopic DermatitisThe study is focused on skin-of-color participants who have moderate-to-severe atopic dermatitis. For the purposes of this research study, “skin-of-color” refers to participants with Fitzpatrick types 4, 5, and 6. Fitzpatrick skin type is a commonly used system to describe a person’s skin … The study is focused on skin-of-color participants who have moderate-to-severe atopic dermatitis. For the purposes of this research study, “skin-of-color” refers to participants with Fitzpatrick types 4, 5, and 6. Fitzpatrick skin type is a commonly used system to describe a person’s skin response to ultraviolet radiation (UVR) exposure. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked. From the previous studies on the study drug, it is seen that the study drug has an acceptable safety and effectiveness in participants with atopic dermatitis. The aim of this study is to get additional information on the safety and effectiveness of the study drug, particularly the information on aspects of atopic dermatitis in skin of color participants.
NCT05590585 STU00218376 |
Study to understand the safety and efficacy of an experimental oral drug for HSThis research is being done to test the safety and efficacy of the study drug, upadacitinib, compared to a placebo (a treatment with no active properties) for the treatment of HS patients. Upadacitinib has been approved for specific medical conditions, but not approved for HS. The use of the study … This research is being done to test the safety and efficacy of the study drug, upadacitinib, compared to a placebo (a treatment with no active properties) for the treatment of HS patients. Upadacitinib has been approved for specific medical conditions, but not approved for HS. The use of the study drug is investigational (experimental) for the purposes of this study. Eligible subjects will be individuals who are at least 12 years of age at screening with a diagnosis of HS for at least 6 months and failed to respond to or are intolerant to anti-TNF alpha therapy or one approved non-anti-TNF biologic therapy for HS. Subjects will have moderate to severe HS.
NCT05889182 STU00219369 |